Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17109018 | AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others | December 2020 | June 2023 | Allow | 30 | 0 | 0 | No | No |
| 17102362 | CELL SUSPENSION FOR USE IN THE TREATMENT OF LOWER EXTREMITY PERIPHERAL ARTERY DISEASE | November 2020 | January 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17063293 | METHOD FOR THE TREATMENT OF MALIGNANCIES | October 2020 | July 2023 | Allow | 34 | 1 | 0 | No | No |
| 16948507 | CELL-BASED THERAPY FOR THE PULMONARY SYSTEM | September 2020 | January 2023 | Allow | 28 | 0 | 0 | No | No |
| 17014688 | STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID | September 2020 | December 2023 | Abandon | 39 | 1 | 0 | No | No |
| 17011658 | LIPOSOMAL PARTICLES, METHODS OF MAKING SAME AND USES THEREOF | September 2020 | September 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16986071 | ACTIVATION OF INNATE IMMUNITY FOR ENHANCED NUCLEAR REPROGRAMMING OF SOMATIC CELLS WITH mRNA | August 2020 | September 2023 | Allow | 37 | 1 | 1 | No | No |
| 16938222 | CONJUGATED POLYMERIC PARTICLE AND METHOD OF MAKING SAME | July 2020 | March 2023 | Allow | 31 | 0 | 0 | No | No |
| 16899989 | EX VIVO PROLIFERATION OF EPITHELIAL CELLS | June 2020 | February 2023 | Allow | 32 | 0 | 0 | No | No |
| 16886289 | GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS RELATING TO COMPLEMENT DEPENDENT CYTOTOXICITY | May 2020 | June 2023 | Allow | 36 | 1 | 0 | No | No |
| 16882812 | RNA HYDROGELS | May 2020 | October 2023 | Abandon | 41 | 1 | 0 | No | No |
| 16869799 | GLAUCOMA TREATMENT | May 2020 | June 2022 | Allow | 25 | 1 | 1 | No | No |
| 16855905 | DOUBLE KNOCKOUT (GT/CMAH-KO) PIGS, ORGANS AND TISSUES | April 2020 | October 2022 | Allow | 30 | 1 | 0 | No | No |
| 16845719 | NANOFIBER SCAFFOLDS FOR BIOLOGICAL STRUCTURES | April 2020 | April 2023 | Allow | 36 | 1 | 0 | No | No |
| 16838746 | METHOD FOR PRODUCING RNA COMPOSITIONS | April 2020 | May 2023 | Allow | 37 | 1 | 0 | No | No |
| 16815356 | SRPX FOR TREATMENT OF CANCER | March 2020 | July 2022 | Allow | 28 | 0 | 0 | No | No |
| 16808984 | Microbubble Nucleic Acid Delivery Platform | March 2020 | April 2023 | Allow | 37 | 1 | 0 | No | No |
| 16801531 | Genome Editing without Nucleases | February 2020 | August 2023 | Abandon | 42 | 1 | 0 | No | No |
| 16799536 | NOVEL RNAi MOLECULE DELIVERY PLATFORM BASED ON SINGLE-siRNA AND shRNA NANOCAPSULES | February 2020 | July 2023 | Abandon | 41 | 1 | 0 | No | No |
| 16798140 | METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PRIMARY AND METASTATIC BASAL-LIKE BREAST CANCER AND OTHER CANCER TYPES | February 2020 | January 2024 | Abandon | 47 | 2 | 0 | No | No |
| 16638972 | METHOD AND COMPOSITION FOR TREATING NEUROPATHIC PAIN | February 2020 | May 2023 | Allow | 39 | 2 | 0 | No | No |
| 16783717 | METHOD FOR INDUCING PRODUCTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR | February 2020 | January 2023 | Allow | 36 | 2 | 0 | No | No |
| 16749012 | PARTICLES COMPRISING A SHELL WITH RNA | January 2020 | March 2023 | Allow | 38 | 1 | 0 | No | No |
| 16738408 | METHOD OF FABRICATING CELL ARRAYS AND USES THEREOF | January 2020 | June 2023 | Abandon | 42 | 1 | 0 | No | No |
| 16734156 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS | January 2020 | April 2023 | Allow | 39 | 3 | 0 | Yes | No |
| 16732770 | NUCLEIC ACID-CATIONIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | January 2020 | July 2023 | Abandon | 43 | 0 | 1 | No | No |
| 16721156 | METHODS AND COMPOSITIONS FOR GENE EDITING IN HEMATOPOIETIC STEM CELLS | December 2019 | May 2023 | Allow | 41 | 2 | 0 | Yes | No |
| 16619733 | SELF-REGULATING AAV VECTORS FOR SAFE EXPRESSION OF MECP2 IN RETT SYNDROME | December 2019 | April 2023 | Allow | 40 | 1 | 1 | No | No |
| 16696769 | CHIMERIC RECEPTOR BINDING PROTEINS FOR USE IN BACTERIAL DELIVERY VEHICLES | November 2019 | January 2023 | Allow | 38 | 1 | 0 | No | No |
| 16614549 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | November 2019 | July 2023 | Allow | 54 | 1 | 2 | Yes | No |
| 16612648 | Systemic Delivery of Polypeptides | November 2019 | March 2023 | Allow | 40 | 1 | 0 | Yes | No |
| 16676413 | ENHANCED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY | November 2019 | January 2023 | Allow | 38 | 2 | 0 | No | No |
| 16674448 | GENE CORRECTION OF POMPE DISEASE AND OTHER AUTOSOMAL RECESSIVE DISORDERS VIA RNA-GUIDED NUCLEASES | November 2019 | April 2023 | Allow | 41 | 2 | 1 | No | No |
| 16668065 | RECOMBINANT ADIPOSE-DERIVED STEM CELL AND RECOMBINANT METHOD THEREOF | October 2019 | November 2022 | Allow | 37 | 2 | 0 | Yes | No |
| 16659986 | TUMOR TREATMENT METHODS USING CELLS THAT LOCALIZE TO THE TUMOR | October 2019 | August 2022 | Allow | 34 | 1 | 0 | Yes | No |
| 16604609 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | October 2019 | April 2023 | Allow | 42 | 1 | 1 | No | No |
| 16600268 | Nanoparticle Modification of Human Adipose-Derived Mesenchymal Stem Cells for Treating Brain Cancer and Other Neurological Diseases | October 2019 | September 2022 | Allow | 35 | 1 | 0 | No | No |
| 16604427 | TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS | October 2019 | November 2022 | Allow | 37 | 2 | 0 | No | No |
| 16597471 | METHODS OF MAKING T CELL COMPOSITIONS | October 2019 | October 2022 | Allow | 36 | 1 | 0 | No | No |
| 16594630 | COMPOSITION FOR TREATING CANCEROUS CELLS AND A METHOD THEREFOR | October 2019 | November 2022 | Abandon | 37 | 1 | 0 | No | No |
| 16589647 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | October 2019 | February 2023 | Allow | 41 | 1 | 0 | No | No |
| 16493573 | METHODS OF TREATING LYSOSOMAL DISORDERS | September 2019 | March 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16492441 | FASL-ENGINEERED BIOMATERIALS WITH IMMUNOMODULATORY FUNCTION | September 2019 | October 2022 | Allow | 37 | 2 | 0 | Yes | No |
| 16322922 | COMPOSITIONS AND METHODS FOR TREATING CEP290 ASSOCIATED DISEASE | August 2019 | September 2022 | Allow | 44 | 2 | 0 | No | No |
| 16482497 | Engineered Cells And Methods Of Use | July 2019 | February 2023 | Allow | 43 | 2 | 1 | No | No |
| 16523328 | METHODS AND COMPOSITIONS FOR TREATING HEMOPHILIA | July 2019 | December 2022 | Allow | 40 | 1 | 0 | No | No |
| 16476865 | EXPRESSION CONSTRUCTS, FUSOGENIC LIPID-BASED NANOPARTICLES, AND METHODS OF USE THEREOF | July 2019 | April 2022 | Allow | 33 | 0 | 1 | Yes | No |
| 16456424 | MATERIALS AND METHODS USEFUL FOR TREATING GLIOBLASTOMA | June 2019 | January 2023 | Allow | 43 | 4 | 1 | Yes | No |
| 16344866 | Transdermal Optogenetic Peripheral Nerve Stimulation | April 2019 | July 2022 | Allow | 38 | 2 | 1 | Yes | No |
| 16324490 | ONCOLYTIC RHABDOVIRUS EXPRESSING IL12 | February 2019 | October 2022 | Allow | 44 | 1 | 1 | No | No |
| 16315458 | COMPOSITIONS AND METHODS COMPRISING IMPROVEMENTS OF CRISPR GUIDE RNAS USING THE H1 PROMOTER | January 2019 | March 2023 | Allow | 50 | 2 | 1 | No | No |
| 16240382 | CHRONIC CAR TREATMENT FOR CANCER | January 2019 | January 2024 | Abandon | 60 | 6 | 0 | Yes | No |
| 16239052 | EXOSOME VESSELS FOR DELIVERY OF MOLECULAR CARGO | January 2019 | July 2023 | Allow | 54 | 6 | 1 | Yes | No |
| 16309412 | GENE THERAPY OF NEURONAL CEROID LIPOFUSCINOSES | December 2018 | December 2023 | Abandon | 60 | 0 | 1 | No | No |
| 16210480 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | December 2018 | January 2022 | Allow | 38 | 2 | 1 | No | No |
| 16307128 | COMPOSITIONS AND METHODS FOR MITOCHONDRIAL GENOME EDITING | December 2018 | May 2023 | Allow | 53 | 3 | 1 | Yes | No |
| 16115140 | MICROFLUIDIC LASER-ACTIVATED INTRACELLULAR DELIVERY SYSTEMS AND METHODS | August 2018 | February 2023 | Allow | 54 | 2 | 1 | Yes | No |
| 15943619 | CELL EXPANSION | April 2018 | March 2022 | Allow | 48 | 3 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner KELLY, ROBERT M works in Art Unit 1631 and has examined 58 patent applications in our dataset. With an allowance rate of 81.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 39 months.
Examiner KELLY, ROBERT M's allowance rate of 81.0% places them in the 53% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by KELLY, ROBERT M receive 1.47 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by KELLY, ROBERT M is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +17.6% benefit to allowance rate for applications examined by KELLY, ROBERT M. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 38.9% of applications are subsequently allowed. This success rate is in the 89% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 95.7% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.